Guía de práctica clínica mexicana para el diagnóstico y tratamiento de las dislipidemias y enfermedad cardiovascular aterosclerótica

• Autores: Abel A. Pavía-López, Marco Antonio Alcocer Gamba, Edith Ruiz Gastelum, J.L. Mayorga Butrón, Roopa Mehta, Filiberto A. Díaz-Aragón, Jorge Antonio Aldrete Velasco, Nitzia López-Juárez, Ivette Cruz Bautista, Adolfo Chávez-Mendoza, Nikos C. Secchi-Nicolás, Francisco J. Guerrero-Martínez, Jorge E. Cossio-Aranda, Victoria Mendoza Zubieta, Guillermo Fanghänel Salmón, Martha Valdivia-Proa, Luis Olmos-Domínguez, Carlos Alberto Aguilar Salinas, Luis Dávila-Maldonado, Armando Vázquez Rangel, Vanina Pavia-Aubry, María de los A. Nava-Hernández, Carlos A Hinojosa Becerril, Juan C. Anda Garay, Manuel O. de los Ríos Ibarra, Ana Berni Betancourt, Julio López-Cuellar, Diego Araiza Garaygordobil, Romina Rivera-Reyes, Gabriela Borrayo Sánchez, Mónica Tapia-Hernández, Claudia V. Cano-Nigenda, Arturo Guerra López, Josué Elías-López, Marco A. Figueroa-Morales, Bertha Beatriz Montaño Velázquez, Liliana Velasco Hidalgo, Ana L. Rodríguez-Lozano, Claudia Pimentel Hernández, María M. Baquero-Hoyos, Felipe Romero-Moreno, Mario Rodríguez-Vega
• Localización: Archivos de cardiología de México, ISSN 1405-9940, ISSN-e 1665-1731, Vol. 92, Nº. 0, 2022, págs. 1-62
• Idioma: español
• Títulos paralelos:
  • Mexican clinical practice guideline for the diagnosis and treatment of dyslipidemias and atherosclerotic cardiovascular disease
• Enlaces
  • Texto completo
• Dialnet Métricas: 7 Citas
• Resumen
  • español

    resumen está disponible en el texto completo

  • English

    Abstract Background: Cardiovascular diseases are the leading cause of mortality worldwide and Mexico is no exception. The epidemiological data obtained in 1990 showed that cardiovascular diseases represented 19.8% of all causes of death in our country. This figure increased significantly to 25.5% for 2015. Some national surveys suggest that more than 60% of the adult population has at least one risk factor for cardiovascular disease (obesity or overweight, hypertension, smoking, diabetes, dyslipidemias). On the other hand, data from the Pan American Health Organization have linked the process of atherosclerosis as the first cause of premature death, significantly reducing life expectancy, which has enormous social repercussions. Objective: This document constitutes the Clinical Practice Guide (CPG) prepared at the initiative of the Mexican Society of Cardiology in collaboration with the Mexican Society of Nutrition and Endocrinology, AC, National Association of Cardiologists of Mexico, AC, Mexican Association for the Prevention of Atherosclerosis and its Complications, AC, National Normative Committee of General Medicine, AC, National College of Geriatric Medicine, AC, College of Internal Medicine of Mexico, AC, Mexican Society of Angiology and Vascular and Endovenous Surgery, AC, Mexican Institute of Research Nephrological, AC and the Mexican Academy of Neurology, A.C.; with the methodological support of the Ibero-American Agency for the Development and Evaluation of Health Technologies, in order to establish recommendations based on the best available evidence and agreed upon by an interdisciplinary group of experts. The objective of this document is to provide evidence-based recommendations to help decision makers in the diagnosis and treatment of dyslipidemias in our country. Material and methods: This document complies with international quality standards, such as those described by the Institute of Medicine of the USA, the Institute of Clinical Excellence of Great Britain, the Scottish Intercollegiate Guideline Network and the Guidelines International Network. A multidisciplinary group of clinical experts and methodologists with experience in systematic reviews of the literature and the development of clinical practice guidelines was formed. A scope document was agreed upon, relevant clinical questions were established, the best available evidence critically evaluated in systematic literature reviews was exhaustively identified, and clinical recommendations were developed. The modified Delphi Panel methodology was used to achieve an adequate level of consensus in each of the recommendations contained in this CPG. Results: 23 clinical questions were agreed upon which gave rise to their respective clinical recommendations. Conclusions: We consider that this document contributes to better clinical decision-making and becomes a point of reference for clinicians and patients in the management of dyslipidemias and this contributes to reducing the morbidity and mortality derived from atherosclerotic cardiovascular events in our country.